Literature DB >> 20565885

A systematic review of population based epidemiological studies in Myasthenia Gravis.

Aisling S Carr1, Chris R Cardwell, Peter O McCarron, John McConville.   

Abstract

BACKGROUND: The aim was to collate all myasthenia gravis (MG) epidemiological studies including AChR MG and MuSK MG specific studies. To synthesize data on incidence rate (IR), prevalence rate (PR) and mortality rate (MR) of the condition and investigate the influence of environmental and technical factors on any trends or variation observed.
METHODS: Studies were identified using multiple sources and meta-analysis performed to calculate pooled estimates for IR, PR and MR.
RESULTS: 55 studies performed between 1950 and 2007 were included, representing 1.7 billion population-years. For All MG estimated pooled IR (eIR): 5.3 per million person-years (C.I.:4.4, 6.1), range: 1.7 to 21.3; estimated pooled PR: 77.7 per million persons (C.I.:64.0, 94.3), range 15 to 179; MR range 0.1 to 0.9 per millions person-years. AChR MG eIR: 7.3 (C.I.:5.5, 7.8), range: 4.3 to 18.0; MuSK MG IR range: 0.1 to 0.32. However marked variation persisted between populations studied with similar methodology and in similar areas.
CONCLUSIONS: We report marked variation in observed frequencies of MG. We show evidence of increasing frequency of MG with year of study and improved study quality. This probably reflects improved case ascertainment. But other factors must also influence disease onset resulting in the observed variation in IR across geographically and genetically similar populations.

Entities:  

Mesh:

Year:  2010        PMID: 20565885      PMCID: PMC2905354          DOI: 10.1186/1471-2377-10-46

Source DB:  PubMed          Journal:  BMC Neurol        ISSN: 1471-2377            Impact factor:   2.474


  57 in total

1.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

2.  The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK.

Authors:  B K MacDonald; O C Cockerell; J W Sander; S D Shorvon
Journal:  Brain       Date:  2000-04       Impact factor: 13.501

3.  Epidemiology of seropositive myasthenia gravis in Greece.

Authors:  K Poulas; E Tsibri; A Kokla; D Papanastasiou; T Tsouloufis; M Marinou; P Tsantili; T Papapetropoulos; S J Tzartos
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-09       Impact factor: 10.154

4.  Incidence and characteristics of Myasthenia gravis in Dar Es Salaam, Tanzania.

Authors:  W B Matuja; E A Aris; J Gabone; E M Mgaya
Journal:  East Afr Med J       Date:  2001-09

5.  Neurological diseases in Karachi, Pakistan--elevated occurrence of subacute sclerosing panencephalitis.

Authors:  K Kondo; T Takasu; A Ahmed
Journal:  Neuroepidemiology       Date:  1988       Impact factor: 3.282

6.  Epidemiology of myasthenia gravis: a population-based study in Stockholm, Sweden.

Authors:  B Kalb; G Matell; R Pirskanen; M Lambe
Journal:  Neuroepidemiology       Date:  2002 Sep-Oct       Impact factor: 3.282

Review 7.  [Prevalence of myasthenia gravis in Antioquia, Colombia].

Authors:  J L Sánchez; C S Uribe; A F Franco; M E Jiménez; O M Arcos-Burgos; L G Palacio
Journal:  Rev Neurol       Date:  2002 Jun 1-15       Impact factor: 0.870

8.  Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece.

Authors:  P Tsiamalos; G Kordas; A Kokla; K Poulas; S J Tzartos
Journal:  Eur J Neurol       Date:  2009-04-03       Impact factor: 6.089

9.  [Clinico-epidemiologic aspects of myasthenia in the Georgian SSR].

Authors:  N B Kvirkveliia
Journal:  Zh Nevropatol Psikhiatr Im S S Korsakova       Date:  1986

10.  Descriptive epidemiology of some rare neurological diseases in Benghazi, Libya.

Authors:  K Radhakrishnan; A K Thacker; J C Maloo; S E Gerryo; M E Mousa
Journal:  Neuroepidemiology       Date:  1988       Impact factor: 3.282

View more
  125 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

2.  Intercommunication between the neuroendocrine and immune systems: focus on myasthenia gravis.

Authors:  Jacqueline Mays; Cherié L Butts
Journal:  Neuroimmunomodulation       Date:  2011-09-22       Impact factor: 2.492

3.  Rituximab in Refractory Myasthenia Gravis: Experience in a Single Healthcare Center in Mexico.

Authors:  Juan Carlos López-Hernández; Javier A Galnares-Olalde; Enrique Gómez-Figueroa; Adib Jorge de Sarachaga; Edwin Steven Vargas-Cañas
Journal:  Cureus       Date:  2021-02-08

4.  Myasthenia gravis: Five new things.

Authors:  Jeffrey M Statland; Emma Ciafaloni
Journal:  Neurol Clin Pract       Date:  2013-04

5.  Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.

Authors:  Chengyong Shen; Yisheng Lu; Bin Zhang; Dwight Figueiredo; Jonathan Bean; Jiung Jung; Haitao Wu; Arnab Barik; Dong-Min Yin; Wen-Cheng Xiong; Lin Mei
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

Review 6.  Myasthenia gravis - autoantibody characteristics and their implications for therapy.

Authors:  Nils Erik Gilhus; Geir Olve Skeie; Fredrik Romi; Konstantinos Lazaridis; Paraskevi Zisimopoulou; Socrates Tzartos
Journal:  Nat Rev Neurol       Date:  2016-04-22       Impact factor: 42.937

7.  Characteristics of obstructive sleep apnea in myasthenia gravis patients: a single center study.

Authors:  Sung Jae Heo; Jin-Sun Jun; Donghwi Park; Ho-Won Lee; Jung-Soo Kim; Jin-Sung Park
Journal:  Neurol Sci       Date:  2019-01-16       Impact factor: 3.307

Review 8.  The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.

Authors:  Inga Koneczny; Judith Cossins; Angela Vincent
Journal:  J Anat       Date:  2013-03-04       Impact factor: 2.610

9.  A cohort study on myasthenia gravis patients in China.

Authors:  Wei Wang; Yu-Ping Chen; Zhong-Kui Wang; Dong-Ning Wei; Ling Yin
Journal:  Neurol Sci       Date:  2013-02-20       Impact factor: 3.307

10.  A genome-wide association study of myasthenia gravis.

Authors:  Alan E Renton; Hannah A Pliner; Carlo Provenzano; Amelia Evoli; Roberta Ricciardi; Michael A Nalls; Giuseppe Marangi; Yevgeniya Abramzon; Sampath Arepalli; Sean Chong; Dena G Hernandez; Janel O Johnson; Emanuela Bartoccioni; Flavia Scuderi; Michelangelo Maestri; J Raphael Gibbs; Edoardo Errichiello; Adriano Chiò; Gabriella Restagno; Mario Sabatelli; Mark Macek; Sonja W Scholz; Andrea Corse; Vinay Chaudhry; Michael Benatar; Richard J Barohn; April McVey; Mamatha Pasnoor; Mazen M Dimachkie; Julie Rowin; John Kissel; Miriam Freimer; Henry J Kaminski; Donald B Sanders; Bernadette Lipscomb; Janice M Massey; Manisha Chopra; James F Howard; Wilma J Koopman; Michael W Nicolle; Robert M Pascuzzi; Alan Pestronk; Charlie Wulf; Julaine Florence; Derrick Blackmore; Aimee Soloway; Zaeem Siddiqi; Srikanth Muppidi; Gil Wolfe; David Richman; Michelle M Mezei; Theresa Jiwa; Joel Oger; Daniel B Drachman; Bryan J Traynor
Journal:  JAMA Neurol       Date:  2015-04       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.